Will a lab test take us a step closer to "personalized medicine"? Approval of a genetic assay for drug utilization suggests so

Article

The US Food and Drug Administration has approved a genetics-based test that detects how certain drugs are utilized in the body. The Invader UGT1A1 Molecular Assay detects variations in the gene UGT1A1, which produces an enzyme that is active in the metabolism of certain drugs, including irinotecan (Camptosar), used to treat colorectal cancer.

Recent Videos
Paul Kruszka, MD
Herbert Bravo, MD
Tina Tan, MD
Paul Kruszka, MD, MPH, FACMG
Stephanie Anne Deutsch, MD, MS, MSCR, FAAP
H. Westley Phillips, MD
David Turkewitz, MD
H. Westley Phillips, MD
David Turkewitz, MD
Related Content
Image credit: © udra11 - stock.adobe.com.

Healthy children in body and mind

Jennifer Lin Uzzell, DNP, APRN, CPNP-PC, PMHS, CLL, EBP-C
December 6th 2024
Article

Lifestyle medicine and mental health management in pediatric primary care promote positive health and holistic well-being.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Study links depression to increased menstrual pain | Image Credit: © Monkey Business - © Monkey Business - stock.adobe.com.

Study links depression to increased menstrual pain

Celeste Krewson, Assistant Editor
December 5th 2024
Article

A new study highlights how depression may drive dysmenorrhea through shared genetic pathways, emphasizing the need for mental health screening and holistic care for women.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Fremanezumab for episodic migraine prevention demonstrates positive phase 3 dataLatest revision | Image Credit: © Jan H. Andersen - © Jan H. Andersen - stock.adobe.com.

Fremanezumab for episodic migraine prevention demonstrates positive phase 3 data

Joshua Fitch, Senior Editor
December 4th 2024
Article

Both monthly migraine days and headache days were reduced vs placebo in patients aged 6 to 17 years.

FDA grants Rare Pediatric Disease to 101-PGC-005 for systemic juvenile idiopathic arthritis | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

FDA grants Rare Pediatric Disease to 101-PGC-005 for systemic juvenile idiopathic arthritis

Joshua Fitch, Senior Editor
December 4th 2024
Article

101-PGC-005 is Type IA prodrug of dexamethasone that targets CD206+ macrophages.

© 2024 MJH Life Sciences

All rights reserved.